Literature DB >> 16167351

Proprotein convertases: "master switches" in the regulation of tumor growth and progression.

Daniel E Bassi1, Jian Fu, Ricardo Lopez de Cicco, Andres J P Klein-Szanto.   

Abstract

Proprotein convertases (PCs) are a group of Ca2+-dependent serine proteases that have homology to the endoproteases subtilisin (bacteria) and kexin (yeast). This group is comprised of less than a dozen members, known as furin/PACE, PC1/PC3, PC2, PC4, PACE4, PC5/PC6, PC7/PC8/LPC, SKI/S1P, and NARC-1/PCSK9. Four PCs (Furin, PACE4, PC5, and PC7) have been localized to several different tissues and epithelial or nervous system tumors. PCs activate their cognate substrates by limited proteolysis at the consensus sequence RXR/KR downward arrow. Many PC substrates are well known cancer-associated proteins such as growth factors, growth factor receptors, integrins, and matrix metalloproteases (MMPs). For example, IGF-1 and its receptor, TGF-beta, VEGF-C, and MT-MMPs have direct roles in tumor progression and metastasis. Furin, a well-studied member of the PC family, has been associated with enhanced invasion and proliferation in head and neck, breast, and lung cancer. Conversely, inhibition of PC activity by PDX or several PC pro-segments, resulted in reduced processing of these key cancer-related substrates in human squamous cell carcinomas (SCC), colon adenocarcinoma, and astrocytoma cell lines. In parallel to these changes in cell proliferation and invasiveness as well as metastatic ability were markedly impaired. By controlling the maturation/activation of key cancer-associated proteins, PCs act as "master switches" at different levels during tumor development and progression. The manifold effects of PCs, influencing tumor cell proliferation, motility, adhesiveness, and invasiveness, should be exploited by further developing competitive/inhibitory therapeutic strategies that would be able to neutralize simultaneously the most salient cancer cell properties. Copyright 2005 Wiley-Liss, Inc

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16167351     DOI: 10.1002/mc.20134

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  87 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

Review 2.  Semaphorin signaling in angiogenesis, lymphangiogenesis and cancer.

Authors:  Atsuko Sakurai; Colleen L Doçi; Colleen Doci; J Silvio Gutkind
Journal:  Cell Res       Date:  2011-12-13       Impact factor: 25.617

Review 3.  Semaphorins in angiogenesis and tumor progression.

Authors:  Gera Neufeld; Adi D Sabag; Noa Rabinovicz; Ofra Kessler
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

4.  Identification of inhibitors using a cell-based assay for monitoring Golgi-resident protease activity.

Authors:  Julia M Coppola; Christin A Hamilton; Mahaveer S Bhojani; Martha J Larsen; Brian D Ross; Alnawaz Rehemtulla
Journal:  Anal Biochem       Date:  2007-01-17       Impact factor: 3.365

5.  Transcriptional profiling of gene expression changes in a PACE-transfected CHO DUKX cell line secreting high levels of rhBMP-2.

Authors:  Padraig Doolan; Mark Melville; Patrick Gammell; Martin Sinacore; Paula Meleady; Kevin McCarthy; Linda Francullo; Mark Leonard; Timothy Charlebois; Martin Clynes
Journal:  Mol Biotechnol       Date:  2008-02-01       Impact factor: 2.695

Review 6.  Proteases for processing proneuropeptides into peptide neurotransmitters and hormones.

Authors:  Vivian Hook; Lydiane Funkelstein; Douglas Lu; Steven Bark; Jill Wegrzyn; Shin-Rong Hwang
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

7.  Opposite roles of furin and PC5A in N-cadherin processing.

Authors:  Deborah Maret; Mohamad Seyed Sadr; Emad Seyed Sadr; David R Colman; Rolando F Del Maestro; Nabil G Seidah
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

8.  Regulation of HIF-1 alpha by the proprotein convertases furin and PC7 in human squamous carcinoma cells.

Authors:  Jian Fu; Jirong Zhang; Yulan Gong; Courtney Lyons Testa; Andres J Klein-Szanto
Journal:  Mol Carcinog       Date:  2014-01-16       Impact factor: 4.784

9.  Successful inhibition of tumor development by specific class-3 semaphorins is associated with expression of appropriate semaphorin receptors by tumor cells.

Authors:  Boaz Kigel; Asya Varshavsky; Ofra Kessler; Gera Neufeld
Journal:  PLoS One       Date:  2008-09-26       Impact factor: 3.240

10.  In vitro and in vivo antitumor effects of the recombinant immunotoxin IL6(T23)-PE38KDEL in multiple myeloma.

Authors:  DE-Jun Guo; Jia-Shan Han; Yan-Song Li; Zeng-Shan Liu; Shi-Ying Lu; Hong-Lin Ren
Journal:  Oncol Lett       Date:  2012-05-25       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.